Abstract
Retinoic acid receptors (RARs) are ligand-dependent transcription factors which are members of the steroid/thyroid hormone receptor gene family. RAR-agonists inhibit the proliferation of many human breast cancer cell lines, particularly those whose growth is stimulated by estradiol (E2) or growth factors. PCR-amplified subtractive hybridization was used to identify candidate retinoid-regulated genes that may be involved in growth inhibition. One candidate gene identified was SOX9, a member of the high mobility group (HMG) box gene family of transcription factors. SOX9 gene expression is rapidly stimulated by RAR-agonists in T-47D cells and other retinoid-inhibited breast cancer cell lines. In support of this finding, a database search indicates that SOX9 is expressed as an EST in breast tumor cells. SOX9 is known to be expressed in chondrocytes where it regulates the transcription of type II collagen and in testes where it plays a role in male sexual differentiation. RAR pan-agonists and the RARĪ±-selective agonist Am580, but not RXR agonists, stimulate the expression of SOX9 in a wide variety of retinoid-inhibited breast cancer cell lines. RAR-agonists did not stimulate SOX9 in breast cancer cell lines which were not growth inhibited by retinoids. Expression of SOX9 in T-47D cells leads to cycle changes similar to those found with RAR-agonists while expression of a dominant negative form of SOX9 blocks RA-mediated cell cycle changes, suggesting a role for SOX9 in retinoid-mediated growth inhibition.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Agadir A, Cornic M, Gourmel B, Lefebvre P, Degos L, Chomienne C . 1994 Cell Mol. Biol. (Noisy-le-grand) 40: 263ā274
Amos B, Lotan R . 1990 Methods Enzymol. 190: 217ā225
Arafa HM, Elmazar MM, Hamada FM, Reichert U, Shroot B, Nau H . 2000 Arch. Toxicol. 73: 547ā556
Arafa HM, Hamada FM, Elmazar MM, Nau H . 1996 J. Chromatogr. A. 729: 125ā136
Bell DM, Leung KK, Wheatley SC, Ng LJ, Zhou S, Ling KW, Sham MH, Koopman P, Tam PP, Cheah KS . 1997 Nat. Genet. 16: 174ā178
Bi W, Deng JM, Zhang Z, Behringer RR, de Crombrugghe B . 1999 Nat. Genet. 22: 85ā89
Brand N, Petkovich M, Krust A, Chambon P, de The H, Marchio A, Tiollais P, Dejean A . 1988 Nature 332: 850ā853
Brooks III SC, Kazmer S, Levin AA, Yen A . 1996 Blood 87: 227ā237
Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L . 1990 Blood 76: 1704ā1709
Chomczynski P, Sacchi N . 1987 Anal. Biochem. 162: 156ā159
Dawson MI, Chao WR, Pine P, Jong L, Hobbs PD, Rudd CK, Quick TC, Niles RM, Zhang XK, Lombardo A, Ely KR, Shroot B, Fontana J . 1995 Cancer Res. 55: 4446ā4451
Desai SH, Boskovic G, Eastham L, Dawson M, Niles RM . 2000 Biochem. Pharmacol. 59: 1265ā1275
Diatchenko L, Lau YF, Campbell AP, Chenchik A, Moqadam F, Huang B, Lukyanov S, Lukyanov K, Gurskaya N, Sverdlov ED, Siebert PD . 1996 Proc. Natl. Acad. Sci. USA 93: 6025ā6030
Easwaran V, Pishvaian M, Salimuddin, Byers S . 1999 Curr. Biol. 9: 1415ā1418
Fanjul AN, Bouterfa H, Dawson M, Pfahl M . 1996 Cancer Res. 56: 1571ā1577
Fenaux P . 1993 Acta Haematol. 89: 22ā27
Fitzgerald P, Teng M, Chandraratna RA, Heyman RA, Allegretto EA . 1997 Cancer Res. 57: 2642ā2650
Fontana JA, Miranda D, Mezu AB . 1990 Cancer Res. 50: 1977ā1982
Forman BM, Casanova J, Raaka BM, Ghysdael J, Samuels HH . 1992 Mol. Endocrinol. 6: 429ā442
Gianni M, Li Calzi M, Terao M, Guiso G, Caccia S, Barbui T, Rambaldi A, Garattini E . 1996 Blood 87: 1520ā1531
Giese K, Kingsley C, Kirshner JR, Grosschedl R . 1995 Genes Dev. 9: 995ā1008
Giese K, Pagel J, Grosschedl R . 1997 Proc. Natl. Acad. Sci. USA 94: 12845ā12850
Giguere V, Ong ES, Segui P, Evans RM . 1987 Nature 330: 624ā629
Graham JD, Hunt SM, Tran N, Clarke CL . 1999 J. Mol. Endocrinol. 22: 295ā304
Graves JA . 1998 Bioessays 20: 264ā269
Grunt TW, Dittrich E, Offterdinger M, Schneider SM, Dittrich C, Huber H . 1998 Br. J. Cancer 78: 79ā87
Hanley NA, Hagan DM, Clement-Jones M, Ball SG, Strachan T, Salas-Cortes L, McElreavey K, Lindsay S, Robson S, Bullen P, Ostrer H, Wilson DI . 2000 Mech. Dev. 91: 403ā407
Hawkins JR . 1995 J. Endocrinol. 147: 183ā187
Healy C, Uwanogho D, Sharpe PT . 1999 Dev. Dyn. 215: 69ā78
Hong WK, Lippman SM . 1995 J. Natl. Cancer Inst. Monogr. 17: 49ā53
Hong WK, Sporn MB . 1997 Science 278: 1073ā1077
Jinno H, Steiner MG, Mehta RG, Osborne MP, Telang NT . 1999 Carcinogenesis 20: 229ā236
Kagechika H, Kawachi E, Hashimoto Y, Himi T, Shudo K . 1988 J. Med. Chem. 31: 2182ā2192
Kent J, Wheatley SC, Andrews JE, Sinclair AH, Koopman P . 1996 Development 122: 2813ā2822
Koopman P . 1999 Cell. Mol. Life Sci. 55: 839ā856
Koopman P . 2001 Exs. 91: 25ā56
Krust A, Kastner P, Petkovich M, Zelent A, Chambon P . 1989 Proc. Natl. Acad. Sci. USA 86: 5310ā5314
Lacroix A, Lippman ME . 1980 J. Clin. Invest. 65: 586ā591
Langenfeld J, Lonardo F, Kiyokawa H, Passalaris T, Ahn MJ, Rusch V, Dmitrovsky E . 1996 Oncogene 13: 1983ā1990
Lefebvre V, de Crombrugghe B . 1998 Matrix Biol. 16: 529ā540
Lefebvre V, Huang W, Harley VR, Goodfellow PN, de Crombrugghe B . 1997 Mol. Cell. Biol. 17: 2336ā2346
Lefebvre V, Li P, de Crombrugghe B . 1998 EMBO J. 17: 5718ā5733
Lotan R . 1980 Biochim. Biophys. Acta 605: 33ā91
Mangelsdorf DJ . 1994 Nutr. Rev. 52: S32āS44
Mangelsdorf DJ, Kliewer SA, Kakizuka A, Umesono K, Evans RM . 1993 Recent Prog. Horm. Res. 48: 99ā121
Mangelsdorf DJ, Ong ES, Dyck JA, Evans RM . 1990 Nature 345: 224ā229
Mangiarotti R, Danova M, Alberici R, Pellicciari C . 1998 Br. J. Cancer 77: 186ā191
Marth C, Mayer I, Daxenbichler G . 1984 Biochem. Pharmacol. 33: 2217ā2221
Nagai K . 2001 Gene 270: 161ā169
Offterdinger M, Schneider SM, Huber H, Grunt TW . 1998 Biochem. Biophys. Res. Commun. 251: 907ā913
Olney PN, Kean LS, Graham D, Elsas LJ, May KM . 1999 Am. J. Med. Genet. 84: 20ā24
Panda DK, Miao D, Lefebvre V, Hendy GN, Goltzman D . 2001 J. Biol. Chem. 276: 41229ā41236
Raffo P, Emionite L, Colucci L, Belmondo F, Moro MG, Bollag W, Toma S . 2000 Anticancer Res. 20: 1535ā1543
Schafer AJ, Foster JW, Kwok C, Weller PA, Guioli S, Goodfellow PN . 1996 Ann. NY Acad. Sci. 785: 137ā149
Seewaldt VL, Johnson BS, Parker MB, Collins SJ, Swisshelm K . 1995 Cell Growth Differ. 6: 1077ā1088
Seewaldt VL, Caldwell LE, Johnson BS, Swisshelm K, Collins SJ, Tsai S . 1997a Exp. Cell Res. 236: 16ā28
Seewaldt VL, Dietze EC, Johnson BS, Collins SJ, Parker MB . 1999 Cell Growth Differ. 10: 49ā59
Seewaldt VL, Kim JH, Caldwell LE, Johnson BS, Swisshelm K, Collins SJ . 1997b Cell Growth Differ. 8: 631ā641
Sekiya I, Koopman P, Tsuji K, Mertin S, Harley V, Yamada Y, Shinomiya K, Niguji A, Noda M . 2001 J. Cell Biochem. 81: Suppl 71ā78
Sekiya I, Tsuji K, Koopman P, Watanabe H, Yamada Y, Shinomiya K, Nifuji A, Noda M . 2000 J. Biol. Chem. 275: 10738ā10744
Shao ZM, Dawson MI, Li XS, Rishi AK, Sheikh MS, Han QX, Ordonez JV, Shroot B, Fontana JA . 1995 Oncogene 11: 493ā504
Sheikh MS, Rochefort H, Garcia M . 1995 Oncogene 11: 1899ā1905
Sheikh MS, Shao ZM, Chen JC, Hussain A, Jetten AM, Fontana JA . 1993 J. Cell Biochem. 53: 394ā404
Sheikh MS, Shao ZM, Li XS, Dawson M, Jetten AM, Wu S, Conley BA, Garcia M, Rochefort H, Fontana JA . 1994 J. Biol. Chem. 269: 21440ā21447
Schneider SM, Offterdinger M, Huber H, Grunt TW . 2000 Cancer Res. 60: 5479ā5487
Smith MA, Parkinson DR, Cheson BD, Friedman MA . 1992 J. Clin. Oncol. 10: 839ā864
Sporn MB, Roberts AB . 1983 Cancer Res. 43: 3034ā3040
Sudbeck P, Scherer G . 1997 J. Biol. Chem. 272: 27848ā27852
Teixeira C, Pratt MA . 1997 Mol. Endocrinol. 11: 1191ā1202
Toma S, Isnardi L, Raffo P, Dastoli G, De Francisci E, Riccardi L, Palumbo R, Bollag W . 1997 Int. J. Cancer 70: 619ā627
van der Burg B, van der Leede BM, Kwakkenbos-Isbrucker L, Salverda S, de Laat SW, van der Saag PT . 1993 Mol. Cell Endocrinol. 91: 149ā157
van der Leede BJ, Folkers GE, van den Brink CE, van der Saag PT, van der Burg B . 1995 Mol. Cell Endocrinol. 109: 77ā86
Watanabe K, Clarke TR, Lane AH, Wang X, Donahoe PK . 2000 Proc. Natl. Acad. Sci. USA 97: 1624ā1629
Willhite CC, Dawson MI, Reichert U . 1996 Drug Metab. Rev. 28: 105ā119
Zhou Q, Stetler-Stevenson M, Steeg PS . 1997 Oncogene 15: 107ā115
Acknowledgements
We are grateful to Dr Benoit de Crombrugghe for providing us with SOX9 plasmids and antibody to SOX9. This research was supported by NIH grant D16636 (HH Samuels), a New York State Department of Health Breast Cancer Award (C015710) (HH Samuels), a Robert Wood Johnson Foundation Grant (038398) (O Afonja), and NIH Grant K12CA01713 (O Afonja).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Afonja, O., Raaka, B., Huang, A. et al. RAR agonists stimulate SOX9 gene expression in breast cancer cell lines: evidence for a role in retinoid-mediated growth inhibition. Oncogene 21, 7850ā7860 (2002). https://doi.org/10.1038/sj.onc.1205985
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205985
Keywords
This article is cited by
-
NR2F1 controls tumour cell dormancy via SOX9- and RARĪ²-driven quiescence programmes
Nature Communications (2015)
-
Expression features of SOX9 associate with tumor progression and poor prognosis of hepatocellular carcinoma
Diagnostic Pathology (2012)
-
MiniSOX9, a dominant-negative variant in colon cancer cells
Oncogene (2011)
-
Molecular Mechanisms of Barrettās Esophagus
Digestive Diseases and Sciences (2011)
-
Ras-association domain family 1C protein promotes breast cancer cell migration and attenuates apoptosis
BMC Cancer (2010)